Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Royalty Pharma Plc Cl A (RPRX)

Royalty Pharma Plc Cl A (RPRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,419,738
  • Shares Outstanding, K 607,111
  • Annual Sales, $ 2,122 M
  • Annual Income, $ 975,040 K
  • 60-Month Beta N/A
  • Price/Sales 11.92
  • Price/Cash Flow 25.04
  • Price/Book 2.56
Trade RPRX with:

Options Overview

Details
  • Implied Volatility 34.77%
  • Historical Volatility 23.88%
  • IV Percentile 0%
  • IV Rank 0.87%
  • IV High 74.60% on 07/06/20
  • IV Low 34.42% on 04/15/21
  • Put/Call Vol Ratio 1.56
  • Today's Volume 443
  • Volume Avg (30-Day) 252
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 23,210
  • Open Int (30-Day) 7,894

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate 0.64
  • Number of Estimates 4
  • High Estimate 0.65
  • Low Estimate 0.61
  • Prior Year N/A
  • Growth Rate Est. (year over year) -99.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.45 +3.51%
on 04/13/21
48.75 -14.11%
on 03/17/21
-5.03 (-10.72%)
since 03/16/21
3-Month
39.63 +5.65%
on 03/05/21
53.23 -21.34%
on 01/19/21
-10.08 (-19.40%)
since 01/15/21

Most Recent Stories

More News
Royalty Pharma Declares Second-Quarter 2021 Dividend

The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2021 of $0.17 per class A share.

RPRX : 41.87 (+0.53%)
SYF or RPRX: Which Is the Better Value Stock Right Now?

SYF vs. RPRX: Which Stock Is the Better Value Option?

SYF : 41.39 (+0.27%)
RPRX : 41.87 (+0.53%)
Royalty Pharma Acquires OXLUMO(TM) Royalty Interest From Dicerna for up to $240 Million

Royalty Pharma plc (Nasdaq: RPRX) ("Royalty Pharma") and Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) ("Dicerna") today announced that Royalty Pharma has acquired Dicerna's royalty interest in OXLUMO(TM)...

RPRX : 41.87 (+0.53%)
DRNA : 28.96 (+1.51%)
Dicerna Sells OXLUMO(TM) (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) ("Dicerna") and Royalty Pharma plc (Nasdaq: RPRX) ("Royalty Pharma") today announced that Royalty Pharma has acquired Dicerna's royalty interest in OXLUMO(TM)...

RPRX : 41.87 (+0.53%)
DRNA : 28.96 (+1.51%)
Royalty Pharma Acquires Royalty Interest in Cabozantinib From GSK

Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in the cabozantinib products Cabometyx and Cometriq from GlaxoSmithKline (GSK) for an upfront payment of $342 million...

GSK : 37.75 (+0.16%)
RPRX : 41.87 (+0.53%)
Royalty Pharma Appoints Henry A. Fernandez as Lead Independent Director

The Board of Directors of Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Henry A. Fernandez as Lead Independent Director. Mr. Fernandez...

RPRX : 41.87 (+0.53%)
Is Royalty Pharma a Biotech Stock Worth Buying?

Royalty Pharma (RPRX), which is known for its unique business in which it buys biopharmaceutical royalties, had an impressive market debut in June 2020. However, its share price has fluctuated considerably...

RPRX : 41.87 (+0.53%)
SYF vs. RPRX: Which Stock Should Value Investors Buy Now?

SYF vs. RPRX: Which Stock Is the Better Value Option?

SYF : 41.39 (+0.27%)
RPRX : 41.87 (+0.53%)
CIXX or RPRX: Which Is the Better Value Stock Right Now?

CIXX vs. RPRX: Which Stock Is the Better Value Option?

CIXX : 15.49 (+0.26%)
RPRX : 41.87 (+0.53%)
Royalty Pharma Reports Q4 2020 and Full-Year Results

-- Double-digit growth in Net cash provided by operating activities (GAAP) and Adjusted Cash Flow

RPRX : 41.87 (+0.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko...

See More

Key Turning Points

3rd Resistance Point 42.77
2nd Resistance Point 42.40
1st Resistance Point 42.13
Last Price 41.87
1st Support Level 41.49
2nd Support Level 41.12
3rd Support Level 40.85

See More

52-Week High 56.50
Fibonacci 61.8% 48.21
Fibonacci 50% 45.65
Fibonacci 38.2% 43.09
Last Price 41.87
52-Week Low 34.80

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar